HUMA

Humacyte Inc. (HUMA) | Rumor.io

Humacyte

HUMA

Attention (50-day avg)0%

Attention rank (50-day avg)#908

Bullish sentiment (50-day avg)75%

Price to earnings ratio-2.1

Market capitalization152M

Earnings per share-0.51

Dividend yield (TTM)—

Revenue (annual)2M

Net income (annual)-40.8M

Social

What share of all stock conversation is about HUMA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.02

Sep 16

Laura from Humacyte says the market is not paying attention to the company and believes they are "incredibly undervalued".
The company has a cash runway that goes well into the second half of 2027, which will help them meet key milestones.
There has been significant insider buying activity, with Dr. Keith Anthony "Tony" Jones purchasing HUMA shares three times in less than a month.

Generated by AI

Sentiment

Of the messages about HUMA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% new	56.67% -28.88	82.95% +14.1	77.98% +3.12
Bearish	0% -100	43.33% +28.88	17.05% -14.1	22.02% -3.12

Bullish· Jun 11

The company has strong Phase 3 data, and the financing raised $50M, with a clean common offering at $1.05.
The asset has a high potential for increased revenue due to its technology being already approved and marketed in another indication, leading to new hospital orders and international partnerships.
The company's technology is expected to be approved in more indications, with a stacked pipeline and a robust hiring plan, and institutional support above $1.00, making it a good time to buy.

Bearish· Aug 12

HUMA reported a $38 million loss for Q2, with sales of $0.41 million, landing within guidance, but still a disappointing performance.
The company's sales numbers are a major concern, and the news of another dilution this year is a significant negative for investors.
HUMA's poor performance and lack of good news has led to a significant decline in the stock, with some investors calling it a "scam" and a "junk" investment, and others advising to sell and avoid further losses.

Generated by AI

Topics

Of the messages about HUMA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	6.25%	14.07%	41.9%
Technical Analysis	0%	93.75%	85.19%	29.68%
Analysts	0%	0%	0%	7.42%
Macro	0%	0%	0.74%	17.65%
Controversies	0%	0%	0%	0.77%
Earnings	0%	0%	0%	2.58%

Announcements· Feb 9

Humacyte, Inc. ($HUMA) announced new U.S. Department of Defense funding for the procurement of bioengineered blood vessels, supporting the acquisition and evaluation of its FDA-approved product, Symvess.
The funding aims to advance Humacyte's technology for vascular repair and establish a standard of care in certain trauma indications, which could lead to increased sales and revenue for the company.
The U.S. DoD funding and FDA approval of Symvess are key catalysts for Humacyte's stock performance, with the company's shares rising over 30% on the news.

Technical Analysis· Mar 11

HUMA has shown a 50%+ move off the lows after a clear oversold 15-minute bullish divergence, marking the intraday bottom.
The coin is approaching crucial resistance and a breakout could accelerate the recovery move towards the target, with a running profit of 53%.
A solid consolidation is forming in a key zone, and the coin may take the liquidity above, with a potential target of 0.028+.

Generated by AI

Community

Of the messages about HUMA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	94.55%	87.56%	60.3%
Newcomers	0%	5.45%	12.44%	39.7%

Regulars· Sep 16

Laura from HCW Wainwright highlights Humacyte's (HUMA) undervalued status, citing the company's potential to meet key milestones and achieve a cash runway well into 2027.
The regulars are eagerly anticipating the company's commercial launch and milestones, with one participant noting that the stock should be worth $35 by next year due to its lack of dilution.
Insider buying activity at HUMA has been significant, with Dr. Keith Anthony "Tony" Jones, a board member since 2024, purchasing shares three times in less than a month, sparking interest in the community.

Newcomers· Aug 19

Newcomers are focused on the clinical trial results of Humacyte's ATEV, which showed it outperformed standard fistula for hemodialysis access, particularly in women and men with obesity/diabetes.
The release of these results on a Globe Newswire was significant, with one user noting it was "really good data" that could help the stock.
Some newcomers are taking a cautious approach, with one user advising patience, while others express distrust or skepticism about the stock's prospects.

Generated by AI

News

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing uni...

1d agomarkets.businessinsider.com

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.

11d agoYahoo Finance

Humacyte at H.C. Wainwright conference: dialysis push takes center stage

14d agoInvesting.com

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 16, 2026, at 11:00am Eastern Time. Management will also b

20d agoYahoo Finance

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has a

20d agoYahoo Finance

Humacyte Gets US FDA Clearance to Extend Symvess Shelf Life to 36 Months

Humacyte (HUMA) said Wednesday the US Food and Drug Administration has authorized an extension of th

21d agoYahoo Finance

Also Discussed

Investors talking about HUMA also mention

#	Name	Attention
1	Allogene Therapeutics IncALLO	0%new
2	Huma FinanceHUMA	0%0
3	Abrdn Healthcare Opportunities FundTHQ	0.01%new
4	SOPHiA GENETICS SA Ordinary SharesSOPH	0%0
5	HUDSON PACIFIC PROPERTIES INCHPP	0%new
6	Corgi Total U.S. Market 2x Daily ETFUSX	0%0
7	Mira Pharmaceuticals, Inc.MIRA	0%0
8	ELP - Companhia Paranaense de Energia - COPEL	——
9	Avient Corp. Common StockAVNT	0%0
10	Crane NXT, Co.CXT	0%0

Humacyte Inc.

Healthcare
Biotechnology

Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable. Its core platform centers on acellular tissue technologies, including human acellular vessels, that are intended to support vascular repair and reconstruction across multiple medical settings. The company’s products and programs address critical needs in areas such as vascular trauma, hemodialysis access, peripheral arterial disease, and other regenerative medicine applications. Humacyte also works on advanced tissue constructs and organ systems, positioning its technology at the intersection of regenerative medicine, bioengineering, and surgical care. Headquartered in Durham, North Carolina, Humacyte serves the healthcare market through its commercial-stage development and manufacturing capabilities.

Website

Location

2525 East North Carolina Highway 54

Durham, NC, 27713

United States

Social

What share of all stock conversation is about HUMA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% -0.02

Sep 16

Laura from Humacyte says the market is not paying attention to the company and believes they are "incredibly undervalued".
The company has a cash runway that goes well into the second half of 2027, which will help them meet key milestones.
There has been significant insider buying activity, with Dr. Keith Anthony "Tony" Jones purchasing HUMA shares three times in less than a month.

Generated by AI

Sentiment

Of the messages about HUMA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% new	56.67% -28.88	82.95% +14.1	77.98% +3.12
Bearish	0% -100	43.33% +28.88	17.05% -14.1	22.02% -3.12

Bullish· Jun 11

The company has strong Phase 3 data, and the financing raised $50M, with a clean common offering at $1.05.
The asset has a high potential for increased revenue due to its technology being already approved and marketed in another indication, leading to new hospital orders and international partnerships.
The company's technology is expected to be approved in more indications, with a stacked pipeline and a robust hiring plan, and institutional support above $1.00, making it a good time to buy.

Bearish· Aug 12

HUMA reported a $38 million loss for Q2, with sales of $0.41 million, landing within guidance, but still a disappointing performance.
The company's sales numbers are a major concern, and the news of another dilution this year is a significant negative for investors.
HUMA's poor performance and lack of good news has led to a significant decline in the stock, with some investors calling it a "scam" and a "junk" investment, and others advising to sell and avoid further losses.

Generated by AI

Topics

Of the messages about HUMA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	6.25%	14.07%	41.9%
Technical Analysis	0%	93.75%	85.19%	29.68%
Analysts	0%	0%	0%	7.42%
Macro	0%	0%	0.74%	17.65%
Controversies	0%	0%	0%	0.77%
Earnings	0%	0%	0%	2.58%

Announcements· Feb 9

Humacyte, Inc. ($HUMA) announced new U.S. Department of Defense funding for the procurement of bioengineered blood vessels, supporting the acquisition and evaluation of its FDA-approved product, Symvess.
The funding aims to advance Humacyte's technology for vascular repair and establish a standard of care in certain trauma indications, which could lead to increased sales and revenue for the company.
The U.S. DoD funding and FDA approval of Symvess are key catalysts for Humacyte's stock performance, with the company's shares rising over 30% on the news.

Technical Analysis· Mar 11

HUMA has shown a 50%+ move off the lows after a clear oversold 15-minute bullish divergence, marking the intraday bottom.
The coin is approaching crucial resistance and a breakout could accelerate the recovery move towards the target, with a running profit of 53%.
A solid consolidation is forming in a key zone, and the coin may take the liquidity above, with a potential target of 0.028+.

Generated by AI

Community

Of the messages about HUMA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	94.55%	87.56%	60.3%
Newcomers	0%	5.45%	12.44%	39.7%

Regulars· Sep 16

Laura from HCW Wainwright highlights Humacyte's (HUMA) undervalued status, citing the company's potential to meet key milestones and achieve a cash runway well into 2027.
The regulars are eagerly anticipating the company's commercial launch and milestones, with one participant noting that the stock should be worth $35 by next year due to its lack of dilution.
Insider buying activity at HUMA has been significant, with Dr. Keith Anthony "Tony" Jones, a board member since 2024, purchasing shares three times in less than a month, sparking interest in the community.

Newcomers· Aug 19

Newcomers are focused on the clinical trial results of Humacyte's ATEV, which showed it outperformed standard fistula for hemodialysis access, particularly in women and men with obesity/diabetes.
The release of these results on a Globe Newswire was significant, with one user noting it was "really good data" that could help the stock.
Some newcomers are taking a cautious approach, with one user advising patience, while others express distrust or skepticism about the stock's prospects.

Generated by AI

Humacyte

Social

Sep 16

Bullish· Jun 11

Bearish· Aug 12

Announcements· Feb 9

Technical Analysis· Mar 11

Regulars· Sep 16

Newcomers· Aug 19

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Humacyte at H.C. Wainwright conference: dialysis push takes center stage

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

Humacyte Gets US FDA Clearance to Extend Symvess Shelf Life to 36 Months

Also Discussed

Humacyte Inc.

Company Information

Location

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Humacyte at H.C. Wainwright conference: dialysis push takes center stage

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

Humacyte Gets US FDA Clearance to Extend Symvess Shelf Life to 36 Months

Also Discussed

Social

Sep 16

Bullish· Jun 11

Bearish· Aug 12

Announcements· Feb 9

Technical Analysis· Mar 11

Regulars· Sep 16

Newcomers· Aug 19